- Home
- ZCMD vs XBIO Comparison
ZCMD vs XBIO Comparison
Compare ZCMD & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- XBIO
- Stock Information
- Founded
- ZCMD 2012
- XBIO N/A
- Country
- ZCMD China
- XBIO United States
- Employees
- ZCMD N/A
- XBIO N/A
- Industry
- ZCMD Other Consumer Services
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ZCMD Real Estate
- XBIO Health Care
- Exchange
- ZCMD Nasdaq
- XBIO Nasdaq
- Market Cap
- ZCMD 29.0M
- XBIO 4.2M
- IPO Year
- ZCMD 2020
- XBIO N/A
- Fundamental
- Price
- ZCMD $1.17
- XBIO $3.52
- Analyst Decision
- ZCMD
- XBIO Hold
- Analyst Count
- ZCMD 0
- XBIO 1
- Target Price
- ZCMD N/A
- XBIO N/A
- AVG Volume (30 Days)
- ZCMD 650.1K
- XBIO 179.8K
- Earning Date
- ZCMD 01-01-0001
- XBIO 08-12-2025
- Dividend Yield
- ZCMD N/A
- XBIO N/A
- EPS Growth
- ZCMD N/A
- XBIO N/A
- EPS
- ZCMD N/A
- XBIO N/A
- Revenue
- ZCMD $15,864,773.00
- XBIO $2,582,728.00
- Revenue This Year
- ZCMD N/A
- XBIO $14.23
- Revenue Next Year
- ZCMD N/A
- XBIO $7.14
- P/E Ratio
- ZCMD N/A
- XBIO N/A
- Revenue Growth
- ZCMD N/A
- XBIO 5.63
- 52 Week Low
- ZCMD $0.95
- XBIO $2.20
- 52 Week High
- ZCMD $2.97
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- ZCMD 48.68
- XBIO 60.67
- Support Level
- ZCMD $1.10
- XBIO $3.52
- Resistance Level
- ZCMD $1.30
- XBIO $4.09
- Average True Range (ATR)
- ZCMD 0.15
- XBIO 0.54
- MACD
- ZCMD -0.01
- XBIO 0.09
- Stochastic Oscillator
- ZCMD 24.57
- XBIO 45.17
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.